Open AccessLiterature Review of Saccharomyces boulardii in the Treatment of Refractory Recurrent Clostridium difficile Infection
Author(s) -
Rachel Warila,
Rebecca Hoover
Publication year - 2017
Publication title -
international journal of food and allied sciences
Language(s) - English
Resource type - Journals
eISSN - 2415-0290
pISSN - 2413-2543
DOI - 10.21620/ijfaas.2017120-26
Subject(s) - saccharomyces boulardii , medicine , clostridium difficile , refractory (planetary science) , gastroenterology , clinical endpoint , placebo , randomized controlled trial , antibiotics , surgery , microbiology and biotechnology , probiotic , pathology , biology , bacteria , genetics , alternative medicine , astrobiology
Objective: To evaluate the efficacy of S. boulardii for the treatment of recurrent C. difficile infections. Methods: Eligible articles included S. boulardii in patients with recurrent C. difficile infection. The primary endpoint examined was clinical resolution of infection with no further recurrences during follow-up. Results: Six studies met inclusion criteria. A case report showed resolution of recurrences in one patient, and an experimental trial showed a trend towards decreased recurrences in patients receiving S. boulardii (85% no further recurrences). Two randomized controlled trials found a significant decrease in recurrences for S. boulardii versus placebo (34.6% vs 64.7%, P=0.04; 16.7% vs 50%, P=0.05). One meta-analysis determined significant efficacy for S. boulardii in reducing relapses (RR 0.59, 95% CI 0.35-0.98), while another concluded there was insufficient evidence to recommend probiotics for C. difficile infection. Conclusions: S. boulardii may be considered for patients with recurrent C. difficile infection, refractory to antibiotic regimens alone.